AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.225

+0.02512.50%

Volume:6.92M

Turnover:1.52M

Market Cap:134.82M

PE:-2.14

High:0.235

Open:0.205

Low:0.200

Close:0.200

52wk High:0.470

52wk Low:0.135

Shares:599.19M

Float Shares:353.07M

Volume Ratio:1.95

T/O Rate:1.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.105

EPS(LYR):-0.060

ROE:-180.22%

ROA:-82.94%

PB:22.48

PE(LYR):-3.77

Loading ...

Overview Company News Filings

Paradigm Biopharmaceuticals' Phase 3 Knee Osteoarthritis Trial to Continue Unchanged Following Safety Board Recommendation

MT Newswires Live

Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook

Simply Wall St.

Exploring 3 Undervalued Small Caps With Insider Buying Across Regions

Simply Wall St.

Paradigm Biopharmaceuticals Completes Drawdown of $3 Million Tranche Under Convertible Note Facility

MT Newswires Live

Paradigm Biopharmaceuticals Completes Enrollment in Knee Osteoarthritis Trial; Shares Gain 7%

MT Newswires Live

Paradigm Biopharmaceuticals Ltd-Results of Share Purchase Plan

THOMSON REUTERS

Paradigm Biopharmaceuticals Ltd-Variation to Convertible Securities Agreement

THOMSON REUTERS

Paradigm Biopharmaceuticals Ltd-Share Purchase Plan - Offer Booklet

THOMSON REUTERS

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

MT Newswires Live

BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement

BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement

Paradigm Biopharmaceuticals - Placement at an Issue Price of a$0.19 per Share

THOMSON REUTERS

Paradigm Biopharmaceuticals - Completes a$14.0 Mln Placement

THOMSON REUTERS

BRIEF-Paradigm Biopharmaceuticals Requests Trading Halt

Paradigm Biopharmaceuticals Ltd - Requests Trading Halt Pending Capital Raising Announcement

THOMSON REUTERS

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Simply Wall St.

PAR Technology Launches Agentic AI Tool to Help Restaurants

MT Newswires Live

Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%

MT Newswires Live

Paradigm Biopharmaceuticals Hits 50% Enrollment in Phase 3 Osteoarthritis Trial; Shares Up 4%

MT Newswires Live

Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/PAR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.225,"timestamp":1787638320000,"preClose":0.2,"halted":0,"volume":6916909,"delay":0,"changeRate":0.12499999999999997,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":599189900,"eps":-0.10495,"marketStatus":"Not Yet Opened","change":0.025,"latestTime":"08-25 16:12:00 AEST","open":0.205,"high":0.235,"low":0.2,"amount":1517565,"amplitude":0.175,"askPrice":0.235,"askSize":157215,"bidPrice":0.22,"bidSize":199003,"shortable":3,"etf":0,"ttmEps":-0.10495,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.2,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":1.946445,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PAR.AU","preClose":0.2,"auctionPrice":0.225,"auctionVolume":263478,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638200268}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-82.94%","roe":"-180.22%","lyrEps":-0.059684,"volumeRatio":1.946445,"shares":599189900,"dividePrice":0,"high":0.235,"amplitude":0.175,"preClose":0.2,"low":0.2,"week52Low":0.135,"pbRate":"22.48","psRate":"15954.76","week52High":0.47,"institutionHeld":0,"latestPrice":0.225,"committee":0.11731,"eps":-0.10495,"divideRate":0,"volume":6916909,"delay":0,"ttmEps":-0.10495,"open":0.205,"prevYearClose":0.34,"prevWeekClose":0.175,"prevMonthClose":0.165,"prevQuarterClose":0.165,"fiveDayClose":0.18,"twentyDayClose":0.165,"sixtyDayClose":0.155,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659184174","title":"Paradigm Biopharmaceuticals' Phase 3 Knee Osteoarthritis Trial to Continue Unchanged Following Safety Board Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2659184174","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659184174?lang=en_us&edition=fundamental","pubTime":"2026-08-13 09:25","pubTimestamp":1786584355,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said an independent Data Safety Monitoring Board recommended that the company's phase 3 clinical trial of a knee osteoarthritis treatment continue without modification, according to a Thursday filing with the Australian bourse.The trial is evaluating injectable pentosan polysulfate sodium in participants with knee osteoarthritis, with the change in pain intensity at day 112 set as the primary endpoint.The safety board issued the recommendation after completing a review of about 80% of the participants who have completed dosing, the company said.The trial's interim analysis remains on track for September.Paradigm Biopharmaceuticals shares gained 1% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651906","title":"Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651906","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651906?lang=en_us&edition=fundamental","pubTime":"2026-08-05 12:36","pubTimestamp":1785904609,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-limiteds-asxpar-profit-outlook","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-limiteds-asxpar-profit-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4023","PAR","PAR.AU","BK4157","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654464009","title":"Exploring 3 Undervalued Small Caps With Insider Buying Across Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2654464009","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654464009?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:09","pubTimestamp":1785236980,"startTime":"0","endTime":"0","summary":"In the last week, the United States market has been flat, but over the past 12 months, it has experienced a 15% rise with earnings forecasted to grow by 17% annually. In this environment, identifying stocks that are potentially undervalued with insider buying can be a strategic approach for investors looking to capitalize on growth opportunities within small-cap companies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/exploring-3-undervalued-small-caps-with-insider-buying-acros-16","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/exploring-3-undervalued-small-caps-with-insider-buying-acros-16","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","ONT.AU","BK4157","RF","BK7508","LU1880398554.USD","PAR.AU","ONT","LU1883839398.USD","LU1880398471.USD","BK4023","BK4211","FRST","BK4120","BK4588","BK7067","PAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651160090","title":"Paradigm Biopharmaceuticals Completes Drawdown of $3 Million Tranche Under Convertible Note Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2651160090","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651160090?lang=en_us&edition=fundamental","pubTime":"2026-07-13 12:00","pubTimestamp":1783915254,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  completed the drawdown of the fourth tranche, valued at $3 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Monday Australian bourse filing.The drawdown provides additional working capital to support its global phase three clinical trial, evaluating the use of injectable pentosan polysulfate sodium to treat knee osteoarthritis. It completed participant enrolment into the study, with 538 participants randomized.After the drawdown, around $7 million remains available under the facility.Its shares rose 2% in recent trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643022728","title":"Paradigm Biopharmaceuticals Completes Enrollment in Knee Osteoarthritis Trial; Shares Gain 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643022728","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643022728?lang=en_us&edition=fundamental","pubTime":"2026-06-15 14:19","pubTimestamp":1781504346,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  completed enrollment in a phase 3 clinical trial to evaluate its Zilosul injectable pentosan polysulfate sodium for the treatment of pain linked to knee osteoarthritis, according to a Monday filing with the Australian bourse.The company said 538 participants have started treatment in the study, surpassing the original target of 466 participants.An interim analysis of the trial remains on track for September, while top-line results are due in the first quarter of 2027, the company said.Paradigm Biopharmaceuticals shares gained 7% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640819499","title":"Paradigm Biopharmaceuticals Ltd-Results of Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640819499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640819499?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:34","pubTimestamp":1780274056,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUEBW2BFG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631507203","title":"Paradigm Biopharmaceuticals Ltd-Variation to Convertible Securities Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2631507203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631507203?lang=en_us&edition=fundamental","pubTime":"2026-04-30 15:03","pubTimestamp":1777532615,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUE8WY1XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631570654","title":"Paradigm Biopharmaceuticals Ltd-Share Purchase Plan - Offer Booklet","url":"https://stock-news.laohu8.com/highlight/detail?id=2631570654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631570654?lang=en_us&edition=fundamental","pubTime":"2026-04-30 11:19","pubTimestamp":1777519174,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUE7KFXRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630351973","title":"Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2630351973","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630351973?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:57","pubTimestamp":1777265829,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630355391","title":"BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630355391","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630355391?lang=en_us&edition=fundamental","pubTime":"2026-04-27 10:35","pubTimestamp":1777257305,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement** Paradigm Biopharmaceuticals PAR.AX slips as much as 17.8% to A$0.185, lowest since September 26, 2024** Drug developer anno","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL6N41A05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630035854","title":"BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630035854","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630035854?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:36","pubTimestamp":1777253761,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln PlacementApril 27 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:COMPLETES A$14.0 MILLION PLACEMENTPLACEMENT AT AN ISSUE PRICE OF A$0.19 PER SHAREFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630733225","title":"Paradigm Biopharmaceuticals - Placement at an Issue Price of a$0.19 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2630733225","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630733225?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630332250","title":"Paradigm Biopharmaceuticals - Completes a$14.0 Mln Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332250","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630332250?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248430,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079621","title":"BRIEF-Paradigm Biopharmaceuticals Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079621?lang=en_us&edition=fundamental","pubTime":"2026-04-23 06:49","pubTimestamp":1776898157,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Requests Trading HaltApril 23 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:REQUESTS TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079644","title":"Paradigm Biopharmaceuticals Ltd - Requests Trading Halt Pending Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079644?lang=en_us&edition=fundamental","pubTime":"2026-04-23 06:48","pubTimestamp":1776898134,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626976473","title":"When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626976473","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626976473?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:33","pubTimestamp":1775680389,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/when-will-paradigm-biopharmaceuticals-limited-asxpar-turn-a-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/when-will-paradigm-biopharmaceuticals-limited-asxpar-turn-a-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4157","PAR.AU","BK7067","BK4023","BK7508","PAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625995855","title":"PAR Technology Launches Agentic AI Tool to Help Restaurants","url":"https://stock-news.laohu8.com/highlight/detail?id=2625995855","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625995855?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:25","pubTimestamp":1775564703,"startTime":"0","endTime":"0","summary":"PAR Technology (PAR) said Tuesday it has launched an agentic AI tool called \"PAR Intelligence\" to help restaurants.PAR Intelligence aims to increase the profitability of multi-unit restaurants by using AI to identify what their best outlets are doing differently, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIX","BK4543","ARTY","AIYY","BK4023","AIPO","BK4157","BK7508","BK4528","BK4587","CHAT","AI","BK4551","BK4585","PAR.AU","BK7067","PAR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624967523","title":"Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624967523","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624967523?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:34","pubTimestamp":1775090076,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.The research collaboration is expected to run for about 12 months, per the filing.Paradigm Biopharmaceuticals shares fell 4% in morning trade on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623320295","title":"Paradigm Biopharmaceuticals Hits 50% Enrollment in Phase 3 Osteoarthritis Trial; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623320295","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623320295?lang=en_us&edition=fundamental","pubTime":"2026-03-31 08:02","pubTimestamp":1774915376,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  achieved 50% enrollment in a phase 3 clinical trial of injectable pentosan polysulfate sodium for the potential treatment of osteoarthritis, according to a Tuesday filing with the Australian bourse.The company said it has started dosing of the final participants required for inclusion in the interim analysis, with those results expected in August.The study's primary endpoint is the change in weekly average of daily pain at day 112, while secondary endpoints include improvements in physical function, imaging-based structural outcomes, and safety assessments.The company's shares gained nearly 4% in recent Tuesday trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620203940","title":"Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203940","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203940?lang=en_us&edition=fundamental","pubTime":"2026-03-20 09:29","pubTimestamp":1773970163,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.The site started screening patients, with the study designed to enrol 466 participants globally.Three clinical trial sites in Moldova are expected to be activated in the coming weeks.Its shares rose 2% in recent trading on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}